GSK updates on UK manufacturing network

Issued: 19th July 2017, London UK

GSK today set out several announcements made by the company to improve the efficiency and competitiveness of its manufacturing network. These include both investments for respiratory and HIV medicines manufacturing in the UK and strategic reviews, including the sale of several products and a proposal to close a UK manufacturing site.

Between now and 2020, the Company plans to invest more than £140million at its Ware, Hertfordshire, Barnard Castle, Co Durham and Montrose, Scotland sites. The investments will support expansion of manufacturing for respiratory and HIV medicines. This new investment is in addition to the £275million announced last year and investment of over £1.2billion in UK manufacturing since 2012.

In pharmaceuticals, the company is to undertake a strategic review of its cephalosporins antibiotics business, with an option to sell the business including the associated manufacturing facilities. These medicines are produced at GSK sites in Ulverston, Cumbria, Verona in Italy and part of its Barnard Castle site. The Company has also decided to outsource some manufacturing activity at its Worthing site in the UK. GSK will continue to manufacture other antibiotics such as Augmentin and will continue to conduct research on new antibiotics. The company has also decided not to proceed with a previously planned investment to build a biopharmaceutical facility in Ulverston as it no longer needs the additional capacity.

In its Consumer Healthcare business, the company intends to sell its Horlicks brand in the UK and is proposing to close the associated manufacturing site in Slough where UK product is made. In addition, GSK intends to sell the MaxiNutrition brand in the UK.  GSK is also exploring options to divest some other smaller non-core nutrition brands.

Overall, GSK employs a total of around 17000 people across the UK of which 5000 are in UK manufacturing operations. The proposals announced today for Worthing and Slough will result in a reduction of approximately 320 permanent jobs over the next 4 years.

Roger Connor, President, GSK Global Manufacturing and Supply said: “We have a substantial manufacturing presence in the UK and continue to support the network with new investment of more than £140million in the next 3 years. At the same time, we have had to make some decisions which we know will cause uncertainty for some of our employees. We will do all we can to support them through this process.”

Philip Thomson, President, Global Affairs, GSK, said: “We are continuing to invest in science and our core businesses in the UK and we continue to see the UK as an attractive place for the life sciences industry. We are working constructively with the Government and others to develop an ambitious plan for the sector as part of the UK’s new industrial strategy.”

None of the announcements made today by the company have resulted from the UK’s decision to leave the European Union.

Notes to editors:

  • GSK has a significant presence in the UK with 9 manufacturing sites, a global R&D site and our corporate headquarters. GSK is one of the largest private R&D investors in the UK spending over a £1billion a year. GSK exports around 80% of our UK manufactured products (pharmaceutical and consumer healthcare).
  • The proposals announced today for Worthing and Slough are subject to employee consultation, which will begin immediately.
  • The combined annual UK sales of Horlicks and Maxi Nutrition are around £30m. Today’s decision does not impact the Horlicks brand in India or south East Asia which accounts for the vast majority of Horlicks global revenues.
  • Cephalosporins are a well-established class of antibiotics used to treat a range of bacterial infections. GSK produces three Cephalosporin antibiotics brands Zinnat/Ceftin, Zinacef and Fortum.

GSK – one of the world’s leading research-based pharmaceutical and healthcare companies – is committed to improving the quality of human life by enabling people to do more, feel better and live longer.  For further information please visit www.gsk.com/about-us.

Cautionary statement regarding forward-looking statements
GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described under Item 3.D 'Principal risks and uncertainties' in the company's Annual Report on Form 20-F for 2016.